Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2019-06-17 Capital/Financing Update
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Cleansing Notice Section 708(A) 1 page 90.0KB
Capital/Financing Update Classification · 95% confidence The document is a Placement Cleansing Notice issued by BARD1 Life Sciences Limited under section 708A(5)(e) of the Corporations Act 2001 (Cth). It announces the completion of a placement raising approximately $5 million through the issue of new shares and provides legal compliance statements related to the issuance of these shares without disclosure under Part 6D.2 of the Act. The content focuses on capital raising activities and compliance notices related to share issuance rather than financial results, management changes, or other report types. The document length is short (2531 characters) and is clearly an announcement related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-06-17 English
Cleansing Notice Section 708(AA) 2 pages 92.3KB
Capital/Financing Update Classification · 95% confidence The document is titled 'ENTITLEMENT ISSUE CLEANSING NOTICE' and discusses a pro rata entitlement offer and a placement to raise capital. It references compliance with the Corporations Act and ASIC modifications, and details the terms of the share issue, including pricing and record dates. There is no financial statement or detailed financial analysis present, nor is this a report or presentation. The document is an announcement related to the company's capital raising activities, specifically a share issue. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 3412 characters, which is consistent with an announcement rather than a full report.
2019-06-17 English
Letter to Optionholders 4 pages 112.0KB
Capital/Financing Update Classification · 95% confidence The document is a detailed letter dated 18 June 2019 from BARD1 Life Sciences Limited to option holders regarding a non-renounceable entitlement offer to raise approximately $2.5 million. It includes specifics about the offer, the placement, the timetable, underwriting details, and the purpose of the funds raised. The content focuses on fundraising activities, share issuance, and capital raising mechanisms. There is no financial statement or report of financial performance, nor is it a regulatory announcement or a proxy solicitation. The document is clearly an update on capital raising activities, including share issuance and placement details, which fits the definition of a Capital/Financing Update.
2019-06-17 English
Trading Halt 2 pages 84.6KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Bard1 Life Sciences Limited regarding a trading halt requested pending an announcement about a potential equity raising. It references ASX Listing Rule 17.1 and specifies the halt duration and reason. There is no financial data, report content, or detailed analysis present. The document is an announcement about a trading halt related to capital raising, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is Capital/Financing Update (CAP).
2019-06-13 English
EUROPEAN PATENT VALIDATED 2 pages 210.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement from BARD1 Life Sciences Limited regarding the validation of a European patent for their lung and colorectal cancer test technology. It details the patent number, countries where it is validated, the patent family, and the intellectual property protection status. There is no financial data, no discussion of financial results, no management discussion of financial performance, no regulatory certifications, or other report types. The content is focused on intellectual property and patent validation news, which is a regulatory announcement about the company's patent portfolio status. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a legal proceeding or M&A activity. It is not a voting result or AGM material. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is about 5,685 characters, which is not extremely short, but the content is clearly an announcement rather than a report or presentation. Therefore, the classification is RNS with high confidence.
2019-06-02 English
R&D Tax Incentive Refund 1 page 187.8KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement (3404 characters) about BARD1 Life Sciences receiving a $520K R&D Tax Incentive refund from the Australian Taxation Office for the 2017/18 financial year. It describes the nature of the refund, the eligible R&D expenditure, and the intended use of the funds. There are no financial statements, detailed financial results, or comprehensive report content. The document is clearly an update on a financing-related event (receipt of a government tax incentive refund) rather than a full financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement since it does not mention any report being published or attached. The content aligns best with a Capital/Financing Update (CAP) as it relates to a financial inflow impacting the company's capital resources. Therefore, the appropriate classification is CAP with high confidence.
2019-05-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.